|Day Low/High||81.85 / 83.48|
|52 Wk Low/High||65.25 / 92.64|
In a "take no pain, take no prisoners" market, health care stocks languish.
Posting results 'not as a bad as we thought' has become a successful strategy. It worked for Bristol.
The pharmaceutical giant has reason to be optimistic about its earnings release tomorrow.
Thus far I am seeing a mixed picture of earnings reports this morning and last night. Visa guided a bit lower on a more costly Visa Europe integration, Whirlpool misses and cuts guidance, and Lilly results were well below on both earnings per share ...
On Tuesday, October 25, Apple reports fiscal fourth quarter results after the markets close.
Since mid- July there have been numerous negative divergences. One clear example is the chart below of new highs. During this three-and-a-half month period the S&P 500 has traded in a range above 2125 (the post-Brexit breakout). Downside attempts li...
The stock's healthy recent pattern appears to be giving way to a fresh bull leg.
Drug trial results dominate the market's biggest movers, while Twilio announces a secondary offering.
U.S. stocks rose Monday as Wall Street looked past Sunday night's bitter presidential debate, focusing instead on oil's 3% rally and the looming start of earnings season.
Zoetis is not averse to a little noise as investors, analysts take notice.
Merck has decided to discontinue the development of its osteoporosis drug and will not seek regulatory approval for its use.
The tactic is a slightly out-of-the-money, bearishly biased vertical put spread expiring in November.
The market continues to defy those players who believe we are seeing the calm before the storm.
Pfizer confirmed its $14 billion acquisition of cancer drugmaker Medivation on Monday.
Besides Tesla, Twitter and Biogen make good candidates.
BMY is unlikely to stay in the low $60s for long.
The failed trial is among the biggest single blows by a major pharma player.
Credit Suisse downgraded Bristol-Myers Squibb to NEUTRAL from OUTPERFORM and lowered its price target to $63 from $86 following the latest announcement on Opdivo.
One day does not make a trend, but one day can certainly reinforce an existing trend.
Mattress Firm soars on takeover bid, while Delta's worldwide computer issues are causing the stock to drop.
Peak Trump. The conditions I anticipated in my previous day's column (Trump's fall) -- a widening in the poll differentials between Trump and Clinton --- is already occurring. Tesla TSLA, Part Deux. The market was up at the get go, but we saw a ve...
Bristol-Myers Squibb fell sharply after its lung cancer treatment failed a clinical trial.
Rarely do investors get to buy these types of quality businesses at such discounted prices.